

This list is for the codes only. Use this list to give to the IT programmers. The long version has additional explanations and notes for many of the codes.

<b>COMPREHENSIVE ICD-9-CM CASEFINDING CODE LIST FOR REPORTABLE TUMORS (EFFECTIVE DATE: 1/1/2010)^</b>	
<b>ICD-9-CM Code^</b>	<b>Explanation of Code</b>
<b>140.0 – 209.36</b>	Malignant Neoplasms
<b>209.70 – 209.79</b>	Secondary neuroendocrine tumors
<b>225.0 – 225.9</b>	Benign neoplasm of brain and spinal cord neoplasm
<b>227.3 – 227.4</b>	Benign neoplasm of pituitary gland, craniopharyngeal duct (pouch) and pineal gland
<b>227.9</b>	Benign neoplasm; endocrine gland, site unspecified
<b>228.02</b>	Hemangioma; of intracranial structures
<b>228.1</b>	Lymphangioma, any site
<b>230.0 – 234.9</b>	Carcinoma in situ
<b>236.0</b>	Endometrial stroma, low grade
<b>237.0 – 237.9</b>	Neoplasm of uncertain behavior [borderline] of endocrine glands and nervous system
<b>238.4</b>	Polycythemia vera
<b>238.6 – 238.79</b>	Other lymphatic and hematopoietic tissues
<b>239.6 – 239.89</b>	Neoplasms of unspecified nature
<b>273.2</b>	Other paraproteinemias
<b>273.3</b>	Macroglobulinemia
<b>288.3</b>	Eosinophilia
<b>288.4</b>	Hemophagocytic syndromes
<b>795.06</b>	Papanicolaou smear of cervix with cytologic evidence of malignancy
<b>795.16</b>	Papanicolaou smear of vagina with cytologic evidence of malignancy
<b>796.76</b>	Papanicolaou smear of anus with cytologic evidence of malignancy
<b>V10.0 – V10.91</b>	Personal history of malignancy
<b>V12.41</b>	Personal history of benign neoplasm of the brain

The following codes are not reportable per se, but they should alert registrars to look for the first malignant neoplasm associated with these codes.

<b>SUPPLEMENTARY LIST #1-ICD-9-CM CODES THAT SHOULD BE FOLLOWED BY or ASSOCIATED WITH A NEOPLASM CODE ^</b>	
<b>ICD-9-CM Code^</b>	<b>Explanation of Code</b>
<b>258.02 – 258.03</b>	Multiple endocrine neoplasia (MEN) type IIA and IIB
<b>285.22</b>	Anemia in neoplastic disease
<b>289.83</b>	Myelofibrosis (NOS) (9961/3)
<b>338.3</b>	Neoplasm related pain (acute, chronic); Cancer associated pain
<b>511.81</b>	Malignant pleural effusion (code first malignant neoplasm if known).
<b>789.51</b>	Malignant ascites (code first malignant neoplasm if known).

**NOTE: Cases with these codes should be screened as registry time allows. These are neoplasm-related secondary conditions for which there should also be a primary diagnosis of a reportable neoplasm.**

<b>SUPPLEMENTARY LIST #2-ICD-9-CM CODE LIST TO SCREEN FOR CANCER CASES NOT IDENTIFIED BY OTHER CODES (EFFECTIVE DATE: 1/1/2010)^</b>	
<b>ICD-9-CM Code^</b>	<b>Explanation of Code</b>
042	Acquired Immunodeficiency Syndrome (AIDS)
079.4	Human papillomavirus
079.50 – 079.59	Retrovirus (HTLV, types I, II and 2)
209.40 – 209.69	Benign carcinoid tumors
210.0 – 229.9	Benign neoplasms (except for 225.0-225.9, 227.3, 227.4, 227.9, 228.02, and 228.1, which are listed in the Reportable list)
235.0 – 236.6, 238.0-239.9	Neoplasms of uncertain behavior (except for 236.0, 238.4, 238.6, 238.71-238.79, 239.6, 239.7, 239.81 and 239.89, which are listed in the Reportable list)
253.6	Syndrome of inappropriate secretion of antidiuretic hormone
259.2, 259.8	Other Endocrine disorders
273.0 – 273.1, 273.9	Disorders of plasma protein metabolism
275.42	Hypercalcemia
277.88	Tumor lysis syndrome following antineoplastic drug therapy
279.00, 279.02 – 279.06	Disorders involving the immune mechanism
279.10, 279.12- 279.13	Deficiency of cell-mediated immunity
279.2 – 279.9	Combined immunity deficiency
284.81 – 284.9	Other and unspecified aplastic anemias
285.0, 285.3	Other and unspecified anemias
288.03	Drug induced neutropenia
289.89	Other specified diseases of blood and blood-forming organs
323.81	Encephalomyelitis; specified cause NEC
379.59	Opsoclonia
528.01	Mucositis due to antineoplastic therapy
630	Hydatidiform Mole
686.01	Pyoderma gangrenosum
695.89	Sweet's syndrome
701.2	Acanthosis nigricans
710.3 – 710.4	Diseases of connective tissue
785.6	Enlargement of lymph nodes
790.93	Elevated prostate specific antigen [PSA]
795.8	Abnormal tumor markers; Elevated tumor associated antigens [TAA]; Elevated tumor specific antigens [TSA]; <b>Excludes: Elevated prostate specific antigen [PSA] (790.93)</b>

<b>SUPPLEMENTARY LIST #2-ICD-9-CM CODE LIST TO SCREEN FOR CANCER CASES NOT IDENTIFIED BY OTHER CODES (EFFECTIVE DATE: 1/1/2010)^</b>	
<b>ICD-9-CM Code^</b>	<b>Explanation of Code</b>
<b>795.81 – 795.89</b>	Abnormal tumor markers
<b>999.31</b>	Infection due to central venous catheter (porta-cath)
<b>999.81</b>	Extravasation of vesicant chemotherapy
<b>E879.2</b>	Adverse effect of radiation therapy
<b>E930.7</b>	Adverse effect of antineoplastic therapy
<b>E933.1</b>	Adverse effect of immunosuppressive drugs
<b>V07.31, V07.39</b>	Other prophylactic chemotherapy
<b>V07.8</b>	Other specified prophylactic measure
<b>V12.72</b>	History of colonic polyps
<b>V15.3</b>	Irradiation: previous exposure to therapeutic or ionizing radiation
<b>V42.81 – V42.82</b>	Organ or tissue replaced by transplant, Bone marrow transplant
<b>V51.0</b>	Encounter for breast reconstruction following mastectomy
<b>V52.4</b>	Breast prosthesis and implant
<b>V54.2</b>	Aftercare for healing pathologic fracture
<b>V58.0 – V58.12</b>	Encounter for radiation and chemotherapy
<b>V58.42</b>	Aftercare following surgery for neoplasm
<b>V66.1 – V66.2</b>	Convalescence following radiotherapy and/or chemotherapy
<b>V67.1 – V67.2</b>	Radiation and chemotherapy follow up
<b>V71.1</b>	Observation for suspected malignant neoplasm
<b>V76.0 – V76.9</b>	Special screening for malignant neoplasm
<b>V78.0 – V78.9</b>	Special screening for disorders of blood and blood-forming organs
<b>V82.71</b>	Screening for genetic disease carrier status
<b>V82.79</b>	Other genetic screening
<b>V82.89</b>	Genetic screening for other specified conditions
<b>V82.9</b>	Genetic screening for unspecified condition
<b>V84.01 – V84.09</b>	Genetic susceptibility to malignant neoplasm
<b>V84.81</b>	Genetic susceptibility to multiple endocrine neoplasia [MEN]
<b>V86.0 – V86.1</b>	Estrogen receptor status
<b>V87.41</b>	Personal history of antineoplastic chemotherapy

<sup>^</sup> *International Classification of Diseases, Ninth Revision, Clinical Modification, 2009.*